Innovent Biologics, Inc.
IVBXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9,421,888 | $6,206,070 | $4,556,380 | $4,269,729 |
| % Growth | 51.8% | 36.2% | 6.7% | – |
| Cost of Goods Sold | $1,510,210 | $1,806,844 | $930,990 | $573,040 |
| Gross Profit | $7,911,678 | $4,399,226 | $3,625,390 | $3,696,689 |
| % Margin | 84% | 70.9% | 79.6% | 86.6% |
| R&D Expenses | $2,681,074 | $2,227,556 | $2,871,220 | $2,478,067 |
| G&A Expenses | $738,046 | $750,278 | $835,488 | $884,027 |
| SG&A Expenses | $5,084,938 | $3,850,971 | $3,426,253 | $3,612,193 |
| Sales & Mktg Exp. | $4,346,892 | $3,100,693 | $2,590,765 | $2,620,142 |
| Other Operating Expenses | -$112,453 | $0 | -$90,198 | -$341,595 |
| Operating Expenses | $7,653,559 | $6,078,527 | $6,207,275 | $5,748,665 |
| Operating Income | -$755,872 | -$1,679,301 | -$3,122,846 | -$2,703,350 |
| % Margin | -8% | -27.1% | -68.5% | -63.3% |
| Other Income/Exp. Net | $0 | $534,890 | $952,377 | $61,633 |
| Pre-Tax Income | -$78,621 | -$1,144,411 | -$2,170,469 | -$2,641,717 |
| Tax Expense | $16,010 | -$116,498 | $8,801 | $87,038 |
| Net Income | -$94,631 | -$1,027,913 | -$2,179,270 | -$2,728,755 |
| % Margin | -1% | -16.6% | -47.8% | -63.9% |
| EPS | -0.058 | -0.66 | -1.46 | -1.88 |
| % Growth | 91.2% | 54.8% | 22.3% | – |
| EPS Diluted | -0.056 | -0.66 | -1.46 | -1.88 |
| Weighted Avg Shares Out | 1,577,183 | 1,559,637 | 1,490,123 | 1,451,465 |
| Weighted Avg Shares Out Dil | 1,627,461 | 1,559,637 | 1,490,123 | 1,455,606 |
| Supplemental Information | – | – | – | – |
| Interest Income | $423,454 | $452,837 | $189,537 | $151,755 |
| Interest Expense | $67,647 | $98,624 | $101,698 | $62,464 |
| Depreciation & Amortization | $275,595 | $385,103 | $319,422 | $204,747 |
| EBITDA | -$480,277 | -$660,684 | -$1,749,349 | -$2,374,506 |
| % Margin | -5.1% | -10.6% | -38.4% | -55.6% |